Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive (loss) income	Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2022		82,923,000
Beginning balance at Dec. 31, 2022	$ 134,333	$ 830	$ 4,185,988	$ (4,070)	$ (4,048,415)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock units (in shares)		382,000
Vesting of restricted stock units	(195)	$ 3	(198)
Exercise of stock options (in shares)		3,000
Exercise of stock options	7		7
Purchase of shares under ESPP (in shares)		62,000
Purchase of shares under ESPP	227	$ 1	226
Issuance of common stock (in shares)		23,000,000
Issuance of common stock	130,291	$ 230	130,061
Stock-based compensation expense	5,843		5,843
Other comprehensive (loss) income	984			984
Net (loss) income	18,930				18,930
Ending balance, shares (in shares) at Mar. 31, 2023		106,370,000
Ending balance at Mar. 31, 2023	$ 290,420	$ 1,064	4,321,927	(3,086)	(4,029,485)
Beginning balance (in shares) at Dec. 31, 2023	192,772,000	192,772,000
Beginning balance at Dec. 31, 2023	$ 194,537	$ 1,905	4,454,756	(1,796)	(4,260,328)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock units (in shares)		811,000
Vesting of restricted stock units	0	$ 8	(8)
Issuance of warrants	$ 2,571		2,571
Exercise of stock options (in shares)	0
Stock-based compensation expense	$ 4,054		4,054
Other comprehensive (loss) income	(312)			(312)
Net (loss) income	$ (69,804)				(69,804)
Ending balance, shares (in shares) at Mar. 31, 2024	193,583,000	193,583,000
Ending balance at Mar. 31, 2024	$ 131,046	$ 1,913	$ 4,461,373	$ (2,108)	$ (4,330,132)